Arun Swarup Menawat net worth and biography

Arun Menawat Biography and Net Worth

CEO of Profound Medical

Dr. Arun Menawat is Chairman and CEO of Profound Medical Inc., a commercial-stage medical technology company that markets real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. Profound’s key product is the TULSA-PRO therapeutic system, designed for precise and customizable ablation of diseased prostate tissue.

Before joining Profound, Arun served as the Chairman and CEO of Novadaq Technologies Inc. for 13 years, guiding the company from a startup to one of the fastest growing, NASDAQ listed medical technology companies in North America, with a market cap of mostly over one billion USD during the final three years of his leadership. Earlier, Arun served as President of Cedara Software Corp., a company that developed the industry’s first medical imaging software platform. Today, Cedara’s imaging platform and its big data collection are part of IBM’s Watson Health.

He obtained a Ph.D. in Chemical Engineering from the University of Maryland, and an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, he was named the EY Ontario Entrepreneur of the Year in the health sciences category.

What is Arun Swarup Menawat's net worth?: The estimated net worth of Arun Swarup Menawat is at least $3.89 million as of May 16th, 2025. Menawat owns 587,089 shares of Profound Medical stock worth more than $3,886,529 as of June 23rd. This net worth approximation does not reflect any other investments that Menawat may own. Learn More about Arun Swarup Menawat's net worth.
How do I contact Arun Swarup Menawat?: The corporate mailing address for Menawat and other Profound Medical executives is 2400 SKYMARK AVENUE UNIT 6, MISSISSAUGA A6, L4W 5K5. Profound Medical can also be reached via phone at (647) 476-1350 and via email at [email protected]. Learn More on Arun Swarup Menawat's contact information.
Has Arun Swarup Menawat been buying or selling shares of Profound Medical?: Arun Swarup Menawat has not been actively trading shares of Profound Medical within the last three months. Most recently, on Friday, May 16th, Arun Swarup Menawat bought 12,027 shares of Profound Medical stock. The stock was acquired at an average cost of $4.73 per share, with a total value of $56,887.71. Following the completion of the transaction, the chief executive officer now directly owns 587,089 shares of the company's stock, valued at $2,776,930.97. Learn More on Arun Swarup Menawat's trading history.

Arun Swarup Menawat Insider Trading History at Profound Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/16/2025	Buy	12,027	$4.73	$56,887.71	587,089
5/15/2025	Buy	10,003	$4.33	$43,312.99	575,062

Arun Swarup Menawat Buying and Selling Activity at Profound Medical

Profound Medical Company Overview

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Today's Range

Now: $6.52

$6.45

$6.72

50 Day Range

MA: $6.78

$5.95

$7.27

2 Week Range

Now: $6.52

$3.76

$8.95

Volume

46,536 shs

Average Volume

171,927 shs

Market Capitalization

$236.94 million

P/E Ratio

N/A

Dividend Yield